Every Form 4 that Connect Biopharma Holdings Limited (CNTB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTB filings page.
Connect Biopharma Holdings Ltd (CNTB) director Kleanthis Gabriel Xanthopoulos acquired 5,000 fully vested ordinary shares on September 30, 2026. The shares were granted under the Non-Employee Director Compensation Program in lieu of a portion of his cash compensation for 2026 annual board retainers, for director service during the third quarter of 2026. His direct holdings following the acquisition were 91,554 ordinary shares.
Connect Biopharma Holdings Ltd director Jean I. Liu acquired 8,984 fully vested ordinary shares on September 30, 2026, under her election to receive shares instead of cash compensation for her 2026 annual board retainers. The shares were granted for her director service during the third quarter of 2026, bringing her direct holdings to 20,763 ordinary shares.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 3,738 Ordinary Shares of the company on June 30, 2026. These fully vested shares were issued at no cash cost to him in lieu of a portion of his 2026 annual board cash retainers for service during the second quarter of 2026.
After this equity award, he directly holds 86,554 Ordinary Shares of Connect Biopharma. The number of shares granted was determined by dividing the elected cash amount by the average closing price of the company’s ordinary shares over the 30 days preceding June 30, 2026, rounded down to the nearest whole share.
Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant as board compensation. She acquired 6,718 ordinary shares at no cash cost, issued as fully vested shares in lieu of cash retainers for her 2026 annual board service during the second quarter of 2026.
After this award, she directly holds 11,779 ordinary shares. The number of shares granted was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares for the 30 days preceding June 30, 2026, then rounding down to the nearest whole share.
Connect Biopharma Holdings Ltd reported an insider-related open-market purchase of its Ordinary Shares. An entity associated with director James Huang, Panacea Venture Healthcare Fund II, L.P., bought 150,000 Ordinary Shares at a weighted average price of $2.4774 per share.
After this transaction, the entity indirectly associated with Huang held 13,310,000 Ordinary Shares. The shares were purchased in multiple trades between $2.37 and $2.52, and Huang disclaims beneficial ownership despite being associated with the fund’s control structure.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 2,816 ordinary shares on March 31, 2026. These fully vested shares were taken in lieu of a portion of cash compensation for his 2026 annual board retainers for service in the first quarter of 2026. After this award, he directly holds 82,816 ordinary shares of the company.
LIU JEAN I reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant of 5,061 ordinary shares as board compensation. The shares are fully vested and were taken in lieu of cash for her 2026 annual board retainers, covering service during the first quarter of 2026.
The number of shares was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares over the 30 consecutive trading days immediately before March 31, 2026, then rounded down to the nearest whole share. This is a routine, compensation-related equity award rather than an open‑market purchase or sale.
Connect Biopharma Holdings Ltd director-linked entity reports major share purchase. An entity associated with James Huang completed an open-market purchase of 1,160,000 Ordinary Shares at $3.45 per share. After this transaction, the filing shows 13,160,000 Ordinary Shares held indirectly. The shares are recorded under Panacea Venture Healthcare Fund II, L.P., and Huang may be deemed to share beneficial ownership but expressly disclaims such beneficial ownership.